These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 14607764)

  • 1. Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins.
    Parody R; Oliver A; Souto JC; Fontcuberta J
    Haematologica; 2003 Nov; 88(11):ECR32. PubMed ID: 14607764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis.
    Alsaleh KA; Al-Nasser SM; Bates SM; Patel A; Warkentin TE; Arnold DM
    Am J Hematol; 2008 Nov; 83(11):876-8. PubMed ID: 18803278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fondaparinux (Arixtra): a new anticoagulant.
    Giangrande PL
    Int J Clin Pract; 2002 Oct; 56(8):615-7. PubMed ID: 12425373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia.
    Efird LE; Kockler DR
    Ann Pharmacother; 2006; 40(7-8):1383-7. PubMed ID: 16788093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases.
    Jappe U; Juschka U; Kuner N; Hausen BM; Krohn K
    Contact Dermatitis; 2004 Aug; 51(2):67-72. PubMed ID: 15373846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Heparin induced thrombocytopenia type II after the use of low-molecular weight heparin. Case report and review of the literature].
    Franke J; Schaeper O; Kayser R; Mahlfeld K
    Unfallchirurg; 2003 Jan; 106(1):77-81. PubMed ID: 12552397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed-type hypersensitivity skin reactions due to heparins and heparinoids. Tolerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinux.
    Koch P
    Contact Dermatitis; 2003 Dec; 49(6):276-80. PubMed ID: 15025697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fondaparinux as anticoagulant in a pregnant woman with heparin allergy.
    Wijesiriwardana A; Lees DA; Lush C
    Blood Coagul Fibrinolysis; 2006 Mar; 17(2):147-9. PubMed ID: 16479197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
    Ludwig RJ; Schindewolf M; Alban S; Kaufmann R; Lindhoff-Last E; Boehncke WH
    Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin: from animal organ extract to designer drug.
    Middeldorp S
    Thromb Res; 2008; 122(6):753-62. PubMed ID: 17996279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application, tolerance and safety of fondaparinux therapy in a German hospital: a prospective single-centre experience.
    Schindewolf M; Scheuermann J; Kroll H; Marzi I; Kaufmann R; Boehncke WH; Ludwig RJ; Lindhoff-Last E
    Thromb Res; 2012 Jan; 129(1):17-21. PubMed ID: 21741076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.
    Calatzis A; Peetz D; Haas S; Spannagl M; Rudin K; Wilmer M
    Am J Clin Pathol; 2008 Sep; 130(3):446-54. PubMed ID: 18701419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids.
    Gerhardt A; Zotz RB; Stockschlaeder M; Scharf RE
    Thromb Haemost; 2007 Mar; 97(3):496-7. PubMed ID: 17334521
    [No Abstract]   [Full Text] [Related]  

  • 16. Antithrombotic drugs in vascular medicine: a historical perspective.
    Schrör K
    Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery.
    Andersen JC
    Semin Thromb Hemost; 2004 Dec; 30(6):609-18. PubMed ID: 15630666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy.
    James AH; Brancazio LR; Ortel TL
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):187-97. PubMed ID: 16166990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
    Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
    Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.
    Wester JP; Leyte A; Oudemans-van Straaten HM; Bosman RJ; van der Spoel JI; Haak EA; Porcelijn L; Zandstra DF
    Neth J Med; 2007 Mar; 65(3):101-8. PubMed ID: 17387236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.